Partnership to advance AavantiBio’s diversified gene therapy pipeline, including the Company’s lead program in Friedreich’s Ataxia (FA)
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
